Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
| ▸ | BACE1 | P56817 | 4/20 | 0.51 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.51 |
| ▸ | KISS1R | Q969F8 | 9/20 | 0.49 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.48 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.48 |
| ▸ | NPY1R | P25929 | 2/20 | 0.47 |
| ▸ | NPY2R | P49146 | 2/20 | 0.47 |
| ▸ | NPY4R | P50391 | 2/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31369291 | 0.83 | KISS1R (0.61) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL13781455 | 0.83 | TFPI (0.53) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL29520890 | 0.83 | BACE1 (0.57) | BACE1BACE2KISS1RVIPR2NPY1R | |
| SCHEMBL13634028 | 0.83 | TFPI (0.53) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL30974094 | 0.82 | KISS1R (0.53) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL31369292 | 0.81 | KISS1R (0.57) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL30974431 | 0.81 | KISS1R (0.53) | TFPIBACE1BACE2KISS1RIL23R | |
| SCHEMBL31462099 | 0.80 | BACE1 (0.66) | TFPIBACE1BACE2VIPR2 | |
| SCHEMBL29778027 | 0.80 | VIPR2 (0.54) | TFPIBACE1BACE2KISS1RVIPR2 | |
| SCHEMBL29520980 | 0.80 | VIPR2 (0.54) | TFPIBACE1BACE2KISS1RVIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304388-B2 | Imaging agents | GE HEALTHCARE LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-8304388-B2 | Imaging agents | GE HEALTHCARE LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191123-A1 | NOVEL IMAGING AGENTS | MMP1, CD68, KIT | TFPI 183/4885BACE1 4028/4885BACE2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.